Although KIR4.1 channel appears to be a plausible target of the antibody response in MS pathogenesis, the subsequent and independent studies have provided inconsistent results and casted doubt regarding whether there is indeed an increase of KIR4.1 autoantibodies in MS patients. Here, KCNJ10 is linked to myeloid sarcoma.